This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
This was a prospective, randomised clinical trial that was carried out in the Leeds and Bradford area of West Yorkshire in northern England. Two randomisations were carried out. First, the 8,407 patients undergoing initial screening were randomly selected from all patients included in family practitioner lists. Second, the 2,324 individuals testing positive were randomised, by a computer-generated block allocation schedule stratified by primary care centre, to eradication therapy or placebo. The length of follow-up of the original trial was 2 years. The current study followed patients for a further 8 years. Thus, the total follow-up was 10 years. The patients were contacted and were sent a postal questionnaire. The final study sample comprised 1,070 patients (46%) who gave fully analysable symptom data at 10 years. Blinding was maintained by a central trials unit that was not involved in patient evaluation.
Analysis of effectiveness
Only patients with complete follow-up data were taken into account in the analysis of effectiveness. The clinical end points used in the study were: the presence of dyspepsia at 10 years; the resolution of dyspepsia at 10 years in those who were symptomatic at original trial entry, and the subsequent development of gastric cancer, peptic ulcer disease and gastroesophageal reflux disease (GERD) during 10-year follow-up.
The presence of dyspepsia was evaluated using the short-form Leeds dyspepsia questionnaire, which assesses both the frequency and severity of four symptoms (indigestion, heartburn, regurgitation and nausea), as well as asking the patient to identify the most troublesome upper gastrointestinal symptom. Dyspepsia symptom status at 10 years was dichotomised into symptomatic or asymptomatic. Sub-group analyses were also performed according to gender and excluding those individuals who, on being informed of their H. pylori status and treatment allocation, requested subsequent eradication therapy from their family practitioner between years 2 and 10.
At baseline, the study groups were well matched with respect to their clinical and demographic characteristics. A baseline comparison was also carried out between individuals who were successfully contacted and those who were not contacted or did not respond, as well as between individuals who agreed to the re-examination of primary care records and those who refused.
Effectiveness results
The overall prevalence of dyspepsia at 10 years was 40%. Of those with dyspepsia at baseline, 60% still had dyspepsia at the 10-year follow-up.
There was a trend toward a reduction in the risk of being symptomatic at 10 years in those assigned to eradication therapy (221 of 547 individuals symptomatic; 40%) in comparison with those assigned to placebo (228 of 523; 43.5%). This resulted in a 3.5% absolute risk reduction (ARR) which did not reach statistical significance. The relative risk (RR) of being symptomatic at 10 years was 0.93 (95% confidence interval, CI: 0.89 to 1.07).
When only those individuals who were symptomatic at original trial entry were considered, there was a non significant trend towards a reduction in the risk of remaining symptomatic at 10 years with eradication therapy (132 of 225 individuals remained symptomatic; 59%) in comparison with placebo (138 of 210; 66%). This gave an ARR of 7%, and the RR of remaining symptomatic at 10 years was 0.89 (95% CI: 0.77 to 1.03).
Similar results were observed in the sub-group analysis according to gender. However, the sub-group analysis that excluded patients who requested H. pylori eradication from their family practitioner between years 2 and 10 increased the impact of H. pylori eradication therapy on dyspepsia symptoms, which was of borderline statistical significance. The RR of being symptomatic at 10 years was 0.76 (95% CI: 0.58 to 1.0; p=0.05).
Other clinical outcomes were comparable between the groups. For example, 75 of those assigned to placebo underwent a total of 92 endoscopies, compared with 75 of those allocated to eradication therapy who underwent 90 endoscopies. No patients were found to have an upper gastrointestinal malignancy. There were a total of 12 peptic ulcers in these
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Clinical conclusions
The effectiveness analysis showed that there was a trend towards a reduction in risk of being symptomatic at 10 years in those assigned to eradication therapy in comparison with those assigned to placebo. However, differences between the groups did not achieve statistical significance.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
Direct costs
The study was carried out from the perspective of the NHS (health service payer). It assessed the total dyspepsia-related resource use per individual at 10 years. The costs were grouped in the following categories:
primary care costs (family practitioner consultations), secondary care costs (outpatient consultations, accident and emergency attendances, and inpatient admissions as a consequence of dyspepsia), costs of prescribed drugs for dyspepsia (using total defined daily doses of acid suppression drugs and number of courses of eradication therapy), and costs of relevant investigations (barium meals, upper gastrointestinal endoscopy, and breath tests).
The unit costs were presented, but the quantities of resources used were not reported. Of the initial study sample of 2,324 patients, only 474 intervention patients and 440 placebo patients were available for the analysis of cost data. The remainder could not be traced, did not respond to the questionnaire, or did not agree to participate. The resource use data were obtained retrospectively by researchers blinded to treatment allocation. The costs came from the British National Formulary and UK national reference costs. The price year was 2002. Discounting might have been relevant, given the long timeframe of the analysis, but it was not applied.
The analysis of the costs was consistent with the NHS perspective, with only the direct medical costs being included. The source of the data was provided for each category of costs and the unit costs were reported. However, information on resource consumption was not provided, which limits the possibility of replicating the analysis in other settings. Statistical analyses were performed, but the impact of altering the cost estimates was not investigated in the sensitivity analysis. In effect, the cost estimates were specific to the study setting. The sample of patients included in the cost analysis was appropriate for the detection of statistically significant differences between groups in terms of the costs. The price year was reported, which will facilitate reflation exercises in other time periods. Despite the long timeframe of the analysis, discounting does not appear to have been carried out.
